SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals moves up as USFDA completes inspection at its exclusive testing facility

09 Mar 2020 Evaluate

SMS Pharmaceuticals is currently trading at Rs. 38.15, up by 1.20 points or 3.25% from its previous closing of Rs. 36.95 on the BSE.

The scrip opened at Rs. 38.50 and has touched a high and low of Rs. 41.75 and Rs. 38.15 respectively. So far 3477 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 69.10 on 11-Mar-2019 and a 52 week low of Rs. 35.60 on 28-Feb-2020.

Last one week high and low of the scrip stood at Rs. 41.75 and Rs. 36.00 respectively. The current market cap of the company is Rs. 330.14 crore.

The promoters holding in the company stood at 67.29%, while Institutions and Non-Institutions held 0.5 % and 32.16% respectively.

The United States Food and Drug Administration (USFDA) has successful completed regulatory inspection at SMS Pharmaceuticals’ exclusive testing facility during March 02, 2020 to March 06, 2020. The regulatory audit resulted in zero observation.

The company is committed to meeting the highest quality standards and is further committed to full compliance with CGMP & GLP regulations at all its manufacturing & Analytical facilities. The 'Central Laboratory Analytical Services' is company’s independent testing laboratory, and this was the first USFDA inspection concluded with zero observations.

SMS Pharmaceuticals is a global player in API manufacturing having strong research and manufacturing team supported by state of art facilities.

SMS Pharmaceuticals Share Price

427.60 3.45 (0.81%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×